Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK 2009

Ravi Kumar Anchoori, Kuzhuvelil B. Harikumar, Venkateswara Rao Batchu, Bharat B. Aggarwal, Saeed R. Khan

Research output: Contribution to journalArticlepeer-review


The NF-κB family of transcription factors plays an important role in determining cell survival during immune, inflammatory, and stress responses. NF-κB activity is frequently deregulated in human cancers and is implicated in the resistance of tumor cells to diverse anticancer agents. We studied the effects of novel analogs of precursors of the natural product simplactone (A) on the activity of IkB kinase and NF-κB. Screening of six compounds for the ability to inhibit TNF-induced NF-κB activity revealed that compound SK2009 was the most potent of these compounds in suppressing NF-κB activation in KBM-5 leukemic cells. Further characterization of SK2009 indicates that this newly synthesized molecule can suppress TNF-induced IκBα kinase activation and inhibit the expression of three NF-κB-dependent gene products, cyclin D1, Bcl-2, and VEGF, in these cells.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalBioorganic and Medicinal Chemistry
Issue number1
StatePublished - Jan 1 2010


  • IKK
  • KBM-5 cells
  • NF-κB
  • Novel chemical entities
  • Simplactones
  • TNF

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Inhibition of IkB kinase and NF-κB by a novel synthetic compound SK 2009'. Together they form a unique fingerprint.

Cite this